The trial has an "adaptive" design and could quickly move from dozens of patients to eventually include thousands, Chief Scientific Officer George Yancopoulos told Reuters.
The dual antibody, called REGN-COV2, is being compared to a placebo treatment in hospitalized COVID-19 patients, and in COVID-19 patients who have symptoms but are not sick enough to be hospitalized. Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer: